Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the...

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the drugmaker's non-constipation irritable bowel syndrome treatment Xifaxan ahead of a Nov. 16 committee meeting. Some experts believe the unexpected questions could complicate approval, although others expect the drug ultimately will be approved.